Clene Inc. (CLNN)
After hours:
| Previous Close | 0.3856 |
| Open | 0.3920 |
| Bid | 0.3666 x 100 |
| Ask | 0.3805 x 200 |
| Day's Range | 0.3700 - 0.3920 |
| 52 Week Range | 0.2500 - 1.0900 |
| Volume | |
| Avg. Volume | 887,576 |
| Market Cap | 47.521M |
| Beta (5Y Monthly) | 0.49 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4700 |
| Earnings Date | Aug 12, 2024 - Aug 16, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.00 |
GlobeNewswireClene to Present at Upcoming May Conferences
SALT LAKE CITY, May 14, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis and multiple sclerosis, today announced that it will participate in the following investor conferences in May. Mizuho Neuroscienc
Simply Wall St.Clene First Quarter 2024 Earnings: Misses Expectations
Clene ( NASDAQ:CLNN ) First Quarter 2024 Results Key Financial Results Net loss: US$11.1m (loss narrowed by 5.9% from...
- GlobeNewswire
Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights
Data from long-term extension of Phase 2 VISIONARY-MS clinical trial of CNM-Au8® demonstrated significant evidence of repair and remyelination across multiple paraclinical endpoints (change from original baseline, p<0.05)Peer-reviewed publication characterized the protein corona of CNM-Au8Company received sub-award of $7.3 million from NIH grant for ALS Expanded Access ProgramCash, cash equivalents and marketable securities of $27.9 million as of March 31, 2024 SALT LAKE CITY, May 08, 2024 (GLOB
